Compare GTY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | VCEL |
|---|---|---|
| Founded | 1955 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1998 | 1996 |
| Metric | GTY | VCEL |
|---|---|---|
| Price | $33.30 | $32.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $32.20 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 670.4K | 487.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.80% | N/A |
| EPS Growth | 8.00 | ★ 60.00 |
| EPS | ★ 1.35 | 0.32 |
| Revenue | $221,727,000.00 | ★ $276,259,000.00 |
| Revenue This Year | $8.65 | $19.09 |
| Revenue Next Year | $7.15 | $17.96 |
| P/E Ratio | ★ $24.81 | $100.88 |
| Revenue Growth | 9.02 | ★ 16.45 |
| 52 Week Low | $25.39 | $29.24 |
| 52 Week High | $34.14 | $48.75 |
| Indicator | GTY | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 38.81 |
| Support Level | $26.74 | $31.34 |
| Resistance Level | $34.02 | $38.15 |
| Average True Range (ATR) | 0.60 | 1.21 |
| MACD | -0.09 | -0.15 |
| Stochastic Oscillator | 49.12 | 32.46 |
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.